Contraception use and attitudes: women’s concerns regarding hormonal contraception and copper intrauterine devices

Author(s):  
Susanna Svahn ◽  
Jenny Niemeyer Hultstrand ◽  
Tanja Tydén ◽  
Maria Ekstrand Ragnar
Author(s):  
Jane S. Sillman ◽  
Ajay K. Singh

The general internist needs to be up to date in contraception management. Each year nearly half of all pregnancies in the United States are unintended. Counseling about contraceptive options, provision of a back-up method, and information about emergency contraception can decrease the risk of unintended pregnancy. This chapter focuses on the aspects of contraception emphasized in Medical Knowledge Self-Assessment Program (MKSAP) 14: hormonal contraception, use of barrier methods, intrauterine devices, and emergency contraception.


Author(s):  
Kristin M Wall ◽  
Etienne Karita ◽  
Julien Nyombayire ◽  
Rosine Ingabire ◽  
Jeannine Mukamuyango ◽  
...  

Abstract Background We explored the role of genital abnormalities and hormonal contraception in HIV transmission among heterosexual serodifferent couples in Rwanda. Methods From 2002-2011, non-antiretroviral treatment using HIV serodifferent couples were followed and sociodemographic and clinical data were collected, family planning provided, and HIV-negative partners retested. Couples were assessed for genital ulcers; non-ulcerative genital sexually transmitted infection (STI) including gonorrhea, chlamydia, and trichomoniasis; and non-STI vaginal infections including bacterial vaginosis and candida. Multivariable models evaluated associations between covariates and HIV transmission genetically linked to the index partner. Results Among 877 couples where the man was HIV-positive, 37 linked transmissions occurred. Factors associated with women’s HIV acquisition included female partner genital ulceration (adjusted hazard ratio [aHR]=14.1) and male partner non-ulcerative STI (aHR=8.6). Among 955 couples where the woman was HIV-positive, 46 linked transmissions occurred. Factors associated with men’s HIV acquisition included female partner non-ulcerative STI (aHR=4.4), non-STI vaginal dysbiosis (aHR=7.1), and male partner genital ulceration (aHR=2.6). Hormonal contraception use was not associated with HIV transmission or acquisition. Conclusions Our findings underscore the need for integrating HIV services with care for genital abnormalities. Barriers (e.g., cost for training, demand creation, advocacy, client education; provider time; clinic space) to joint HIV/STI testing need to be considered and addressed.


Contraception ◽  
2016 ◽  
Vol 94 (6) ◽  
pp. 641-649 ◽  
Author(s):  
H. Pamela Pagano ◽  
Lauren B. Zapata ◽  
Erin N. Berry-Bibee ◽  
Kavita Nanda ◽  
Kathryn M. Curtis

JAMA ◽  
2022 ◽  
Vol 327 (1) ◽  
pp. 59
Author(s):  
Marie Hargreave ◽  
Lina S. Mørch ◽  
Jeanette F. Winther ◽  
Kjeld Schmiegelow ◽  
Susanne K. Kjaer

2020 ◽  
Vol 85 (1) ◽  
pp. 93-97
Author(s):  
Cheríe S. Blair ◽  
Sue Li ◽  
Gordon Chau ◽  
Leslie Cottle ◽  
Paul Richardson ◽  
...  

2020 ◽  
Vol 46 (1) ◽  
pp. 8-16 ◽  
Author(s):  
Kathryn M Curtis ◽  
Philip C Hannaford ◽  
Maria Isabel Rodriguez ◽  
Tsungai Chipato ◽  
Petrus S Steyn ◽  
...  

ObjectiveTo update a 2016 systematic review on hormonal contraception use and HIV acquisition.MethodsWe searched Pubmed and Embase between 15 January 2016 and 26 June 2019 for longitudinal studies comparing incident HIV infection among women using a hormonal contraceptive method and either non-users or users of another specific hormonal contraceptive method. We extracted information from newly identified studies, assessed study quality, and updated forest plots and meta-analyses.ResultsIn addition to 31 previously included studies, five more were identified; three provided higher quality evidence. A randomised clinical trial (RCT) found no statistically significant differences in HIV risk among users of intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG implant) or the copper intrauterine device (Cu-IUD). An observational study found no statistically significant differences in HIV risk among women using DMPA, norethisterone enanthate (NET-EN), implants (type not specified) or Cu-IUD. Updated results from a previously included observational study continued to find a statistically significant increased HIV risk with oral contraceptives and DMPA compared with no contraceptive use, and found no association between LNG implant and HIV risk.ConclusionsHigh-quality RCT data comparing use of DMPA, LNG implant and Cu-IUD does not support previous concerns from observational studies that DMPA-IM use increases the risk of HIV acquisition. Use of other hormonal contraceptive methods (oral contraceptives, NET-EN and implants) is not associated with an increased risk of HIV acquisition.


2020 ◽  
Vol 9 (7) ◽  
pp. 2023
Author(s):  
Ahinoam Lev-Sagie ◽  
Osnat Wertman ◽  
Yoav Lavee ◽  
Michal Granot

The pathophysiology underlying painful intercourse is challenging due to variability in manifestations of vulvar pain hypersensitivity. This study aimed to address whether the anatomic location of vestibular-provoked pain is associated with specific, possible causes for insertional dyspareunia. Women (n = 113) were assessed for “anterior” and “posterior” provoked vestibular pain based on vestibular tenderness location evoked by a Q-tip test. Pain evoked during vaginal intercourse, pain evoked by deep muscle palpation, and the severity of pelvic floor muscles hypertonicity were assessed. The role of potential confounders (vestibular atrophy, umbilical pain hypersensitivity, hyper-tonus of pelvic floor muscles and presence of a constricting hymenal-ring) was analyzed to define whether distinctive subgroups exist. Q-tip stimulation provoked posterior vestibular tenderness in all participants (6.20 ± 1.9). However, 41 patients also demonstrated anterior vestibular pain hypersensitivity (5.24 ± 1.5). This group (circumferential vestibular tenderness), presented with either vestibular atrophy associated with hormonal contraception use (n = 21), or augmented tactile umbilical-hypersensitivity (n = 20). The posterior-only vestibular tenderness group included either women with a constricting hymenal-ring (n = 37) or with pelvic floor hypertonicity (n = 35). Interestingly, pain evoked during intercourse did not differ between groups. Linear regression analyses revealed augmented coital pain experience, umbilical-hypersensitivity and vestibular atrophy predicted enhanced pain hypersensitivity evoked at the anterior, but not at the posterior vestibule (R = 0.497, p < 0.001). Distinguishing tactile hypersensitivity in anterior and posterior vestibule and recognition of additional nociceptive markers can lead to clinical subgrouping.


Author(s):  
Sulistyowati Tuminah Darjoko ◽  
Aprildah Nur Sapardin

<p>Background<br />In Indonesia, cancer prevalence according to the Basic Health Research 2013 was 1.4 per 1000 inhabitants and the most common cancer in hospitalized patients in 2010 was breast cancer (28.7%). Hormonal contraception (HC) use increases the breast cancer risk, even though HC has been used by 210 million women in the world. We aimed to define the association of HC with breast tumors based on clinical breast examination (CBE).</p><p>Methods<br />A case-control design using secondary data from the baseline of the Cohort Study on the Risk Factors of Non-Communicable Disease (RFNCD) in 2011-2012 in 5 villages in Central Bogor District, Bogor City. Samples consisted of 152 cases and 152 controls. Cases comprised palpable tumors in one or both breasts CBE (+). Controls had no tumors in both breasts /CBE(-). Data were analyzed by logistic regression.</p><p>Results<br />Odds Ratio (OR) of CBE + was 1.83 (95% CI: 1.11-3.04; p=0.019) for HC user and 1.62 (95% CI: 1.01-2.60; p=0.044) for blood total cholesterol level &lt;200 mg/dL. OR of group CBE(+) was 1.01 (current smoking) and 0.49 (former smoking) compared with nonsmoking (p=0.082); OR was also 1.21 for subjects with one child and 1.77 for those without children, compared with those who had ³2 children (p=0.454).</p><p>Conclusion <br />Hormonal contraception use increases breast tumor risk 1.8-fold after controlling for total cholesterol, smoking status and parity. With the several limitations of this advanced analysis, investigations focused on types and duration of HC use are still necessary.</p>


Sign in / Sign up

Export Citation Format

Share Document